Loading...
Watson Pharma Private Limited — Propranolol Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #7 for Propranolol · $837.6K export value · DGFT Verified
Watson Pharma Private Limited is the #7 Indian exporter of Propranolol with $837.6K in export value and 45 verified shipments. Watson Pharma Private Limited holds a 1.4% market share in Propranolol exports across 1 countries. The company exports 14 pharmaceutical products worth $63.4M across 7 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $9.3M | 186 | 47.9% |
| UNITED KINGDOM | $3.2M | 111 | 16.3% |
| AUSTRALIA | $2.1M | 43 | 11.1% |
| NETHERLANDS | $1.1M | 141 | 5.5% |
| SPAIN | $958.5K | 72 | 4.9% |
| MALTA | $890.6K | 334 | 4.6% |
| FRANCE | $766.2K | 19 | 3.9% |
| NIGERIA | $254.1K | 20 | 1.3% |
| POLAND | $237.8K | 27 | 1.2% |
| CANADA | $200.0K | 4 | 1.0% |
India exports Propranolol to 99 countries. The top destination is UNITED STATES (47.9%), followed by UNITED KINGDOM and AUSTRALIA.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| MILPHARM LIMITED, | UNITED KINGDOM | $850.0K | 17 |
| APOTEX PTY LTD | AUSTRALIA | $700.0K | 14 |
| ACTAVIS LABORATORIES FL, INC. | UNITED STATES | $660.5K | 36 |
| RELONCHEM LTD CHESHIRE HOUSE, | UNITED KINGDOM | $559.5K | 22 |
| XXNEAXXPHAXXACEXXICAXX LXX (NXX | UNITED STATES | $550.0K | 11 |
India exported $17.3M worth of Propranolol through 3,988 shipments from 196 suppliers to 99 countries, serving 363 buyers globally. Watson Pharma Private Limited contributes $837.6K to this total, accounting for 1.4% of India's Propranolol exports.
Watson Pharma Private Limited's average Propranolol shipment value is $18.6K per consignment, based on 45 shipments totaling $837.6K.
Watson Pharma Private Limited ranks #7 among 196 Indian Propranolol exporters with a 1.4% market share. The top 3 exporters are PAR FORMULATIONS PRIVATE LIMITED ($5.5M), AUROBINDO PHARMA LTD ($2.9M), IPCA LABORATORIES LIMITED ($2.8M). Watson Pharma Private Limited processed 45 shipments to 1 destination countries.
What Watson Pharma Private Limited must comply with to export Propranolol to its top destination countries
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Approval Process
Exporters ranked immediately above and below #7 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | IPCA LABORATORIES LIMITED | $2.8M | 55 | 3 | $50.0K |
| 4 | INTAS PHARMACEUTICALS LIMITED | $2.1M | 420 | 5 | $4.9K |
| 7 | WATSON PHARMA PRIVATE LIMITED ★ | $837.6K | 45 | 1 | $18.6K |
| 8 | AUROBINDO PHARMA LIMITED | $833.6K | 72 |
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 843 | 21.1% |
| DELHI AIR CARGO ACC (INDEL4) | 776 | 19.5% |
| SAHAR AIR | 502 | 12.6% |
| DELHI AIR | 420 | 10.5% |
| NHAVA SHEVA SEA (INNSA1) | 145 | 3.6% |
| MUNDRA SEA (INMUN1) | 134 | 3.4% |
| Delhi Air | 109 | 2.7% |
| Bombay Air | 106 | 2.7% |
Watson Pharma Private Limited also exports these cardiovascular products. Each links to the detailed product page.
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Watson Pharma. The Israel-Iran conflict has disrupted key shipping routes in the Red Sea, leading to increased freight costs and extended transit times. These disruptions have particularly impacted time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and inventory management. (pharmaceuticalcommerce.com)
Conversely, the US-China trade tensions have opened avenues for Indian exporters to strengthen their foothold in the US market. India's pharmaceutical exports to the US surged by 20.4% to approximately $10.5 billion in FY25, despite challenges such as pricing pressures and regulatory scrutiny. (economictimes.indiatimes.com) This growth underscores the potential for companies like Watson Pharma to expand their presence in the US market.
The recent India-European Union Free Trade Agreement (FTA), signed in January 2026, is poised to eliminate tariffs on pharmaceuticals, enhancing market access for Indian exporters. This development offers Watson Pharma an opportunity to increase its exports to the EU, provided it meets the stringent regulatory standards set by the European Medicines Agency (EMA). (en.wikipedia.org)
Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. India has made significant strides in this area, with the number of FDA-approved manufacturing sites surpassing those in the US as of 2024. Instances of non-compliance have also decreased, reflecting improved adherence to quality standards. (business-standard.com) For Watson Pharma, maintaining and enhancing compliance with FDA, WHO GMP, and EMA standards is crucial to sustaining and expanding its export markets.
The evolving regulatory environment, including the EU's Falsified Medicines Directive, necessitates robust traceability and anti-counterfeiting measures. Watson Pharma must invest in advanced serialization and tracking systems to ensure compliance and maintain trust with international partners.
Watson Pharma Private Limited exports 14 products worth $63.4M. Beyond Propranolol, top products include Gabapentin, Alprazolam, Hydrochlorothiazide, Prednisone, Dapagliflozin. View the complete Watson Pharma Private Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Propranolol — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Watson Pharma Private Limited's Propranolol exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Watson Pharma Private Limited
Full Company Profile →
14 products · $63.4M total trade · 7 categories
| ACCORD HEALTHCARE, SLU | SPAIN | $446.7K | 42 |
| BROCACEF NL : HUB | NETHERLANDS | $441.6K | 55 |
| NOUMED LIFE SCIENCES LIMITED | UNITED KINGDOM | $435.6K | 16 |
| ACCORD HEALTHCARE SLU | SPAIN | $423.7K | 24 |
| AMNEAL PHARMACEUTICALS LLC NJ | UNITED STATES | $400.0K | 8 |
India's Propranolol is purchased by 363 buyers worldwide. The top buyer is MILPHARM LIMITED, (UNITED KINGDOM), followed by APOTEX PTY LTD and ACTAVIS LABORATORIES FL, INC..
Post-Brexit UK Marketing Authorisation via national procedure. Separate from EU approval since January 2021.
Timeline: 12–15 months
GMP & Export Requirements
UK GMP compliance; MHRA inspection of manufacturing site
Manufacturer Import Authorisation (MIA) held by UK importer; Qualified Person (QP) batch release
Note: Post-Brexit: EU GMP certificates no longer automatically valid in UK. Separate MHRA recognition required.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
| 4 |
| $11.6K |
| 9 | MARKSANS PHARMA LIMITED | $683.4K | 28 | 1 | $24.4K |
Watson Pharma Private Limited ranks #7 among 196 Indian Propranolol exporters. Average shipment value of $18.6K compared to the market average of $88.4K. The closest competitors by value are IPCA LABORATORIES LIMITED and INTAS PHARMACEUTICALS LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 99+ countries, 363+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Watson Pharma Private Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Propranolol. For current shipment-level data, contact TransData Nexus.